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ABSTRACT
Alternative splicing has emerged as an important
target for molecular therapies. Splice-switching
oligonucleotides (SSOs) modulate alternative
splicing by hybridizing to pre-mRNA sequences
involved in splicing and blocking access to the tran-
script by splicing factors. Recently, the efficacy of
SSOs has been established in various animal
disease models; however, the application of SSOs
against cancer targets has been hindered by poor
in vivo delivery of antisense therapeutics to tumor
cells. The apoptotic regulator Bcl-x is alternatively
spliced to express anti-apoptotic Bcl-xL and pro-
apoptotic Bcl-xS. Bcl-xL is upregulated in many
cancers and is associated with chemoresistance,
distinguishing it as an important target for cancer
therapy. We previously showed that redirection
of Bcl-x pre-mRNA splicing from Bcl-xL to -xS
induced apoptosis in breast and prostate cancer
cells. In this study, the effect of SSO-induced Bcl-x
splice-switching on metastatic melanoma was as-
sessed in cell culture and B16F10 tumor xenografts.
SSOs were delivered in vivo using lipid
nanoparticles. Administration of nanoparticle with
Bcl-x SSO resulted in modification of Bcl-x
pre-mRNA splicing in lung metastases and
reduced tumor load, while nanoparticle alone
or formulated with a control SSO had no effect.
Our findings demonstrate in vivo anti-tumor
activity of SSOs that modulate Bcl-x pre-mRNA
splicing.
INTRODUCTION
Over 90% of multi-exon pre-mRNA transcripts undergo
alternative splicing (1) and up to one-half of
disease-causing mutations affect splicing (2). Thus, in
addition to its signiﬁcant contribution to proteome
diversity, alternative splicing constitutes an important
therapeutic target (3). Splice-switching oligonucleotides
(SSOs) modulate alternative splicing by hybridizing
to pre-mRNA sequences involved in splicing and
blocking access by various splicing factors (4,5). Unlike
siRNA and traditional antisense approaches, which lead
to RNA degradation by RISC and RNase H-mediated
cleavage, respectively, direction of pre-mRNA splicing
requires that the SSO-targeted RNA is not degraded.
This is achieved by altering the oligonucleotide
sugar-phosphate backbone as in, for example, the
20-O-methoxyethyl (MOE) ribose modiﬁcation (6,7). In
order to realize their full therapeutic utility, SSOs must
be efﬁciently delivered to the pharmacological site of
action in vivo (8). This can be achieved by exploiting the
inherent pharmacodynamic properties of the SSO chemis-
try (9,10), conjugation of cell penetrating peptides (11–13),
and the use of nanoparticle carriers (14). As a result, in vivo
efﬁcacy has been established for SSOs in animal models of
inﬂammatory disease, b-thalassemia and Duchenne
muscular dystrophy (DMD) [For a recent review, see
(15)], and early phase clinical trials using SSOs to treat
DMD have yielded promising results (16,17).
Previously, this laboratory and others applied SSOs
to manipulate the splicing pattern of the apoptotic regu-
lator Bcl-x. Through alternative splicing, the Bcl-x gene
yields two major protein isoforms with opposing func-
tions, anti-apoptotic Bcl-xL and pro-apoptotic Bcl-xS
(18) (Figure 1A). Bcl-xL is upregulated in a number of
cancers and confers resistance to a broad range of
chemotherapeutic drugs (19). Bcl-xS antagonizes the
anti-apoptotic activity of Bcl-xL and another anti-
apoptotic protein, Bcl-2 (20,21). Redirection of Bcl-x
splicing from Bcl-xL to -xS induced apoptosis and
increased chemosensitivity in cancer cells in culture (22–
24); however, the anti-tumor effect of this strategy remains
to be demonstrated in vivo.
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cancers expressing high levels of Bcl-xL represent good
candidates for treatment with Bcl-x SSO (23). Metastatic
melanoma is an aggressive malignancy with poor progno-
sis and disease progression is associated with increased
Bcl-xL expression (25,26). Xenografts of murine B16F10
melanoma cells provide a good model of this aggressive
cancer because they express Bcl-xL and are syngeneic to
C57BL/6 mice, obviating the need for immunocomprom-
ised animals and providing a more realistic environment
for drug testing. In this model, B16F10 murine melanoma
cells localize to the lungs shortly after injection into the
tail vein, providing a concise and predictable experimental
time-course. In addition, the cell line used here expressed
luciferase, providing an easily quantiﬁed measure of the
tumor load. We previously failed to detect activity
of systemically-delivered free SSOs in tumor xenografts.
Thus, for this work we employed a liposome–DNA-
polycation (LPD) nanoparticle (NP) formulation
designed by the Huang laboratory (27–29), which
delivered siRNA to tumor cells in the B16F10 xenograft
model (30,31). In previous work, Huang and colleagues
demonstrated enhanced tumor cell-speciﬁc uptake of this
NP formulation by surface-modiﬁcation with anisamide,
a ligand of the sigma receptor, which is upregulated in
many cancers (32,33) and is expressed in B16F10 cells
(27,30,31,34).
Our ﬁndings show that delivery of Bcl-x SSO by the
LPD NP resulted in modiﬁcation of Bcl-x mRNA
splicing in lung metastases and reduction of tumor load.
This marks the ﬁrst demonstration of SSO-induced
splicing modiﬁcation in tumor cells in vivo and provides
support for Bcl-x splice-switching as a potential anti-
tumor strategy.
MATERIALS AND METHODS
Materials
20-O-methoxyethyl (MOE)-phosphorothioate SSOs
(Figure 1B) were synthesized by ISIS Pharmaceuticals
(Carlsbad, CA, USA). The Bcl-x SSO was targeted to
the 50-splice site of exon II in Bcl-x pre-mRNA (50-TGG
TTCTTACCCAGCCGCCG-30, ISIS 105751) (35). An
oligonucleotide targeted to aberrantly spliced human
b-globin intron (50-GCTATTACCTTAACCCAG-30,
ISIS 18204) (10) was used as negative control. For
nanoparticle preparation cholesterol, protamine sulfate,
calf thymus DNA and cloning water were purchased
from Sigma-Aldrich (St Louis, MO, USA). DOTAP
stock solution (20mg/ml) was purchased from Avanti
Polar Lipids (Alabaster, AL, USA).
Cell culture and transfection
B16F10 mouse melanoma cells expressing sigma receptors
were used as model cells in this study (36). B16F10 cells
stably expressing the ﬁreﬂy luciferase gene were provided
by Dr Pilar Blancafort (University of North Carolina,
Department of Pharmacology, NC, USA) (31). The cells
were maintained in high-glucose Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine
serum and a 5% penicillin/streptomycin solution
(GIBCO, Grand Island, NY, USA) at 37 C and 5%
CO2. Cells were seeded in 24- or 6-well plates at
7.0 10
5 and 5.0 10
5 cells/well, respectively,  24h
prior to transfection. Cells were transfected
with LipofectAmine 2000 (Invitrogen) in Opti-MEM
(Invitrogen) per the manufacturer’s recommendation.
RNA Isolation and analysis
Total RNA from cells or tissue was isolated using TRI
Reagent (Molecular Research Center, Cincinnati, OH,
USA) according to the manufacturer’s protocol using
800ml for  5mg tissue samples. Next, 200ng of total
RNA was subjected to RT–PCR (50-CATGGCAGCAG
TGAAGCAAG-30, Bcl-x forward primer; 50-GCATTGT
TCCCGTAGAGATCC-30, Bcl-x reverse primer; 50-GTG
CAGCGCAACCACGAGAC-30, Mcl-1 forward primer;
50-GCAGCACATTTCTGATGCCG-30, Mcl-1 reverse
primer) with rTth polymerase (Applied Biosystems,
Foster City, CA, USA). Cycles of PCR proceeded
at 95 C for 3min, followed by 22 cycles of 95 C for 30s,
56 C for 30s, and 72 C for 1min. The PCR contained
Cy5-conjugated dCTP (GE Healthcare) for visualiza-
tion. The PCR products were separated on a
Bcl-xL Bcl-xS
Anti-apoptotic Pro-apoptotic
A
B
Bcl-x
pre-mRNA
Bcl-x
spliced mRNA
II III
+ SSO
II III II III
O
O
O
O
P S
–
O O
O
P
O
O
O
O
S
–
O BASE
Me
BASE
Me
Figure 1. Direction of Bcl-x alternative splicing by SSO. (A) Use of the
downstream or upstream alternative 50-splice site within exon II of
Bcl-x pre-mRNA yields anti-apoptotic Bcl-xL or pro-apoptotic Bcl-xS,
respectively. SSO targeted to the downstream splice site redirects the
splicing machinery to the upstream alternative splice site, resulting in a
simultaneous decrease in production of Bcl-xL and increase in produc-
tion of Bcl-xS.( B) Chemical structure of MOE phosphorothioate (PS)
oligonucleotide. The MOE ribose modiﬁcation confers RNase-H
non-competence and increased afﬁnity for target mRNA, while the
PS inter-nucleotide linkage improves serum stability and bioavailability.
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bands were visualized on a Typhoon 9400 Imager (GE
Healthcare). Images were quantiﬁed using ImageQuant
analysis software (Version 5.2, Molecular Dynamics).
The percentage of Bcl-xS in each lane was determined by
dividing the intensity of the 162-bp band (Bcl-xS) by the
total intensities of the 351 (Bcl-xL) and 162-bp (Bcl-xS)
bands. The identity of the 162-bp band was conﬁrmed
by sequencing by the UNC-CH Genome Analysis Facility.
Cell viability assay
Cell viability in response to SSO treatment was assessed,
with slight modiﬁcations, by a previously described
clonogenic assay (23). Brieﬂy, 24h after oligonucleotide
transfection in six-well plates, 250 cells were re-plated
in 10-cm plates. After 10days under normal culture con-
ditions surviving colonies were stained with 2% methylene
blue (Sigma) in 50% ethanol for 10min. Colonies larger
than 50 cells were counted. As a positive control for the
assay, cells were treated with 1mM staurosporine (STS).
Western blot analysis
Cells (5.0 10
5cells/well in a six-well plate) were washed
twice with ice-cold PBS and lysed in RIPA buffer
(radioimmune precipitation assay buffer; 50mM Tris–
HCl, 150mM NaCl, 5mM EDTA, 1% Triton X-100,
0.1% SDS and 1% sodium deoxycholate) and a cocktail
ofproteaseinhibitors(Sigma).Totalproteinwasquantiﬁed
with the Quick Start Bradford Protein Assay Kit (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). Total protein
(20mg) was separated by electrophoresis on a 4–12%
pre-cast Bis–Tris gel (Invitrogen) and electrotransferred
to a polyvinylidene diﬂuoride (PVDF) membrane.
Membranes were stained with Ponceau’s stain to conﬁrm
equal loading and transfer. Membranes were blocked for
1h in BLOTTO (5% w/v non-fat dry milk in TBS, 0.1%
Tween) or StartingBlock Buffer (Pierce) and incubated
overnight at 4 C with primary antibodies: polyclonal
Bcl-x antibody (1:2000; BD Transduction Labs), poly-
clonal PARP antibody (1:2000; Cell Signaling 9452) and
mouse anti-b-actin monoclonal antibody (1:10000;
Sigma). Membranes were then incubated for 1h with
horseradish peroxidase-conjugated anti-mouse (1:100000;
Sigma) or goat anti-rabbit (1:10000; Abcam) secondary
antibodies. Blots were developed with ECL Plus reagents
(GE Healthcare) and exposed to ﬁlm (GE Healthcare).
Bcl-xL, Bcl-xS, b-actin, cleaved PARP and full-length
PARP migrated at 30, 22, 42, 89 and 116kDa, respectively.
b-Actin was used to conﬁrm equal protein loading.
Preparation of SSO-containing nanoparticles
LPD NPs were prepared as described earlier (30,31).
Brieﬂy, naked NP were obtained by quickly mixing
150ml suspension A (16.6mM liposomes (DOTAP/choles-
terol molar ratio=1:1, and 400mg/ml protamine in 5%
dextrose) with 150ml solution B (320mg/ml oligonucleo-
tide and 320mg/ml calf thymus DNA in 5% dextrose)
followed by incubation at room temperature for 10min.
The naked NP suspension (300ml) was further incubated
with 75.6ml micellar solution of DSPE-PEG2000-anisamide
(10mg/ml) [synthesized in the Huang lab as reported
earlier (34)] at 50 C for 10min and then allowed
to stand at room temperature for 10min. The resulting
formulation was used within 20min for the following
experiments. These methods resulted in encapsulation of
>90% oligoncuelotide or siRNA in previous studies
(28,37,38).
Animal studies
Female C57BL/six mice of ages 6–8 weeks (16–18g) were
purchased from Charles River Laboratories (Wilmington,
MA, USA). All experiments performed on the animals
were in accordance with and approved by the
Institutional Animal Care and Use Committee at the
University of North Carolina. The mouse model was
established by i.v. injection of 2 10
5 luciferase-expressing
B16F10 cells on Day 0. Animals were i.v. injected with
vehicle only (PBS), NP only (2.4mg/kg), control
or Bcl-x SSO NP (2.4mg/kg), or free control or Bcl-x
SSO (2.4 or 10mg/kg) on Days 3–6 after tumor inocula-
tion. On Day 7, some animals were euthanized for analysis
of RNA splicing. For animals treated with free SSO, only
RNA was analyzed. For animals treated with NP, blood
was collected for analysis of toxicity marker. On Day 17
the remaining animals were euthanized for the analysis
of tumor load. Tumor load was determined by measuring
luciferase activity within tumor-bearing lungs,
as described earlier (30,31).
Toxicity assays
Twenty-four hours after the ﬁnal injection, blood samples
were collected and serum was isolated. Analyses of serum
aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) were performed at the Animal
Clinical Laboratory Core Facility (University of North
Carolina) using a Vitro 250 Chemical Analyzer
(Ortho-Clinical Diagnostics, Rochester, NY, USA).
Serum interleuikin-12 was measured with the
enzyme-linked immunosorbant assay (ELISA) according
to the manufacturer’s protocol (BD Biosciences, San
Diego, CA, USA). As a negative control, ALT/AST
serum levels from untreated tumor-free mice were also
measured.
Statistical analysis
Luciferase data were analyzed by one-way analysis of
variance (ANOVA) and Tukey’s post-test using Prism
statistical software (GraphPad, version 4.03).
RESULTS
Modiﬁcation of Bcl-x pre-mRNA in melanoma cells
Transfection of B16F10 cells with MOE-PS Bcl-x SSO
targeted to the downstream 50-splice site of Bcl-x exon
2 (Figure 1) induced a dose-dependant shift in splicing
of Bcl-x pre-mRNA from anti-apoptotic Bcl-xL
to pro-apoptotic Bcl-xS, while a control SSO had no
effect on splicing (Figure 2A and B). Consistent with
these results, probing of total protein from treated cells
8350 Nucleic Acids Research, 2010,Vol.38, No. 22with anti-Bcl-x antibody showed SSO-dependent reduc-
tion in the level Bcl-xL protein (Figure 2C). We were
unable to detect the expected Bcl-xS protein because the
endogenous level of murine Bcl-xS expression was below
the threshold required by available antibodies
(Supplementary Figure S1). Importantly, SSO treatment
resulted also in a dose-dependant decrease in cell viability,
as evidenced by a clonogenic cell death assay (Figure 3A).
This was accompanied by cleavage of poly (ADP-ribose)
polymerase (PARP), indicating that the observed cell
death was due to apoptosis (Figure 3B). These effects
were absent in untreated and mock-transfected cells, and
cells transfected with a control SSO. In addition, the Bcl-x
SSO had no effect on the pre-mRNA splicing of Mcl-1, a
closely related gene that shares sequence homology at the
50-splice site, supporting sequence speciﬁcity of the Bcl-x
SSO (Supplementary Figure S2).
Activity of Bcl-x SSO in vivo
To facilitate SSO delivery to cancer cells in tumor-bearing
mice, an LPD NP developed by the Huang laboratory was
used (30,31). The SSO and a carrier DNA (calf thymus
DNA) were complexed by protamine into a compact core
which was then coated with cationic lipids to form the NP
(Figure 4). The surface of the NP was further modiﬁed
with an anisamide ligand-conjugated polyethylene glycol
(PEG)-lipid for targeting the sigma receptor-expressing
B16F10 cells. This NP formulation could efﬁciently,
speciﬁcally and with low toxicity deliver siRNA
to tumor cells in the B16F10 tumor model, as shown
earlier (30,31).
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Figure 2. SSO induced Bcl-x splice-switching in B16F10 murine
melanoma cells. (A) RT–PCR analysis of Bcl-x mRNA from cells trans-
fected with control and Bcl-x SSO 24h posttransfection. The Bcl-x SSO
induces dose-dependant switching of Bcl-x mRNA splicing from
anti-apoptotic Bcl-xL to pro-apoptotic Bcl-xS. Error bars indicate
mean±SD (n=3). (B) Sequence analysis of the RT–PCR product
corresponding to Bcl-xS showing exons 2 and 3 joined at the
upstream alternative splice site. (C) Immunoblot analysis of cells
treated with 100nM Bcl-x SSO 48h posttransfection. The SSO
induces a reduction in the Bcl-xL protein isoform. Detection of
b-actin conﬁrms equal loading.
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Figure 3. Bcl-x SSO induces cell death in B16F10 murine melanoma
cells. (A) Effect of Bcl-x and control SSO on cell viability as determined
by a clonogenic assay. Top panel shows images of representative plates
at 80nM concentration. Bottom left panel expresses viability of
SSO-treated cells relative to untreated cells. Error bars indicate
mean±SD (n=3–4). Bottom right panel shows viability of cells
treated with 1mM staurosporine (STS) relative to DMSO-treated
cells. (B) Western blot of protein from cells treated with control and
Bcl-x SSOs for 24h. The presence of PARP cleavage in Bcl-x
SSO-treated cells conﬁrms that the observed decrease in cell viability
is due to apoptosis. Detection of b-actin conﬁrms equal loading.
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shortly after injection into the tail vein of C57BL/6
mice. In the absence of treatment, the mice die  22 days
following inoculation (30). This rapid course of disease
dictated the treatment protocol (‘Materials and
Methods’ section). RT–PCR analysis of total RNA from
the tumor-bearing lungs of animals euthanized on Day 7
showed induction of Bcl-xS mRNA expression in animals
treated with the Bcl-x SSO NP formulation. This effect
was dose-dependant, as increasing the number of injec-
tions resulted in a greater degree of Bcl-x splice-switching
from Bcl-xL to Bcl-xS mRNA in the tumor nodules
(Supplementary Figure S3). In contrast, Bcl-xS mRNA
levels in animals treated with control SSO NP formulation
or free SSO were no different than in animals treated with
PBS only (Figure 5A and Supplementary Figure S4).
Modiﬁcation of Bcl-x splicing in the liver was barely
detectable in Bcl-x SSO NP-treated animals and undetect-
able in animals treated with control SSO NP or PBS only
(Figure 5A). As a measure of tumor load, luciferase
activity was assayed in lysates from tumor-bearing lungs
of animals euthanized on Day 17. A dramatic reduction in
luciferase activity was seen in animals treated with Bcl-x
SSO NP compared to animals treated with NP only,
control SSO NP, or PBS only (Figure 5B and C).
Statistical analysis (ANOVA, Tukey’s post-test) revealed
that the reduction in luciferase activity in animals treated
with Bcl-x SSO NP was signiﬁcant compared to animals
treated with PBS only (P<0.001), NP only (P<0.05) and
control SSO NP (P<0.05) (Figure 5B).
Toxicity studies
To determine the potential toxicities of NP and SSO treat-
ment, serum levels of toxicity markers were analyzed in
mice euthanized on Day 7 following tumor inoculation.
Tissues with a leaky endothelial wall, such as the liver,
allow signiﬁcant uptake of NP (39). Accordingly, we
analyzed serum aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels as markers
of liver toxicity. Mean ALT and AST levels among treat-
ment groups were within the normal range (Figure 6A and
B). To test the possibility that components of the NP
formulation might trigger an inﬂammatory response,
serum levels of the pro-inﬂammatory cytokine IL-12
were also analyzed. Elevated IL-12 levels relative to
the PBS control were observed in NP treatment groups
(Empty NP, P<0.01; Control SSO P<0.001)
(Figure 6C).
DISCUSSION
Alternative splicing has emerged as an important target
for molecular therapies (15). Clinical trials using SSOs to
treat DMD have yielded promising preliminary results
(16,17), while numerous recent reports have conﬁrmed
the in vivo efﬁcacy of SSOs in treating animal models
of disease (15). SSOs have been applied against cancer
targets in vitro (22,23,40), however in vivo validation of
their efﬁcacy has been hindered by the poor delivery
of antisense therapeutics to tumor cells in vivo (8,41).
Here we show that an SSO in LPD NP formulation was
effective in delivery to tumor cells in the B16F10 model
system (27,30,31).
Our data indicate that SSO-induced redirection of Bcl-x
pre-mRNA splicing from Bcl-xL to -xS induced apoptosis
and subsequent cell death in a dose-dependant manner
in B16F10 melanoma cells in culture (Figures 2 and 3).
In vivo, redirection of Bcl-x pre-mRNA splicing was
associated with a signiﬁcant reduction of tumor burden
in rapidly growing and highly tumorigenic B16F10 lung
metastases (Figure 5A–C). This ﬁnding is consistent with
our in vitro data, as well as previous work in prostate and
breast cancer cells (22,23). Interestingly, in this model
both in cell culture and in vivo xenografts, modiﬁcation
of Bcl-x pre-mRNA splicing alone induced cell death,
whereas in non-small cell lung carcinoma (A549) cells
adjuvant chemotherapy was needed (24). Bcl-xL expres-
sion may therefore be critical for survival of B16F10
cells, consistent with reports that increased Bcl-xL expres-
sion is associated with melanoma progression and
SSO
Calf Thymus DNA Protamine
Liposomes
PEG lipids,
anisamide
Figure 4. Schematic depiction of the preparation of SSO encapsulated
LPD NP. The SSO was encapsulated into a condensed core with a high
molecular weight polyanion (calf thymus DNA) and protamine, which
was then coated with cationic liposomes. PEG lipids were inserted into
the resultant bilayer to shield the positive charge and prevent aggrega-
tion in circulation. Anisamide, a commonly used targeting ligand that
binds the sigma receptor, was conjugated to the distal end of the PEG
lipids.
8352 Nucleic Acids Research, 2010,Vol.38, No. 22metastasis (25,26). Thus, other pharmacological agents
that target Bcl-xL may warrant further investigation in
metastatic melanoma.
Our cell culture data are consistent with the predicted
SSO mechanism of action. Namely, that Bcl-x
SSO-induced modulation of Bcl-x pre-mRNA splicing
reduced the level of Bcl-xL, and increased the level
of Bcl-xS splice variants, causing apoptosis of cancer
cells. This is evident at the RNA level, and is further
supported by the dramatic reduction of Bcl-xL protein
and by induction of PARP cleavage (Figure 2C, 3C).
Although SSO induced Bcl-xS mRNA, we were unable
to conﬁrm concomitant production of Bcl-xS protein by
immunoblotting procedures. This was in spite of screening
several commercially available antibodies and including
attempts to concentrate the protein by immunopre-
cipitation prior to western analysis. This is likely because
the maximum level of endogenous Bcl-xS protein
that could be induced by the SSO was below that which
could be detected by available antibodies (Supplementary
Figure S1).
In vivo, RT–PCR analysis of total RNA from
tumor-bearing lungs demonstrated that Bcl-x splicing
was shifted  10% from Bcl-xL to the -xS splice variant.
Yet this treatment led to marked reduction of tumor load
in treated animals. Two interpretations of these results are
possible. One, that in vivo even a minor reduction of
Bcl-xL levels and concomitant increase in Bcl-xS, leads to
death of cancer cells or at least inhibits their proliferation.
However, it is also possible that the cells which took up
the SSO more efﬁciently were more effectively killed
by apoptosis and thus eliminated from the tissue subjected
to subsequent analysis. If this is the case, RT–PCR under-
estimates the actual level of SSO-induced splice-switching.
BH3 mimetics comprise a novel class of cancer drugs
that competitively antagonize the Bcl-2 anti-apoptotic
proteins (42). For example, the small molecule ABT-737
binds Bcl-2, Bcl-xL and Bcl-w proteins with nanomolar
afﬁnity. It induced apoptosis in lymphoma and small-cell
lung carcinoma cells in culture, and caused tumor regres-
sion and improved survival in preclinical studies (43).
By modifying the splicing pattern of Bcl-x, the SSO can
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Nucleic Acids Research, 2010,Vol.38, No. 22 8353be thought of as prompting the tumor cell to produce an
endogenous BH3 mimetic, Bcl-xS, capable of antagonizing
Bcl-2 and Bcl-xL and promoting apoptosis.
NPs are known to accumulate non-speciﬁcally in the
liver due to the fenestrated vasculature (39). We did not
observe signiﬁcant Bcl-x splice-switching in the liver
(Figure 5A), and ALT and AST serum levels of the treat-
ment groups was within the normal range (Figure 6A and
B). This suggests that liver uptake of the NP was limited
and did not translate into signiﬁcant biological activity
or toxicity. In some tumor-bearing, control mice AST
and AST values were >100U/L suggesting that this
could be a rare response to tumor burden. We did detect
a modest elevation of serum IL-12 levels in NP treatment
groups relative to the PBS control (Figure 6C). A previous
report with the LPD NP showed more pronounced induc-
tion of inﬂammatory toxicity at doses  1.2mg/kg (29,30).
However, that study analyzed local toxicity from lung
lysate, whereas we analyzed serum from systemic circula-
tion. It is unclear whether this small but statistically
signiﬁcant increase is biologically relevant. Elevated
IL-12 could be due to unmethylated CpG motifs present
in the calf thymus DNA component of the NP. While we
cannot exclude the possibility that the observed IL-12
increase contributed to the antitumor effect of the Bcl-x
SSO, this seems unlikely because IL-12 induction was
observed in all NP treatment groups, whereas reduction
of tumor load was only evident in animals treated with the
Bcl-x SSO.
The inclusion of calf thymus DNA in the NP compli-
cates the use of this formulation from a pharmaceutics
and regulatory perspective. Recently, Chono et al. (38)
replaced calf thymus DNA with a high molecular weight
anionic polysaccharide, hyaluronic acid, resulting in a NP
containing cationic liposome, protamine and hyaluronic
acid (LPH). The LPH formulation delivered siRNA
in vivo with potency similar to that of the LPD formula-
tion; however, induction of both IL-6 and IL-12 cytokines
by LPH was signiﬁcantly lower than that of the corres-
ponding LPD containing the calf thymus DNA. The LPH
NP formulation could be employed for delivery of SSOs
and other antisense therapeutics to tumors in future
studies.
Our results extend previous ﬁndings on the LPD NP
formulation, which delivered siRNA to the cytoplasm,
the site of dicer activity, to oligonucleotides that
function in the nucleus, the site of splicing modulation.
Thus, through delivery of SSOs, liposome-based NP
formulations may be used not only to downregulate,
but also to upregulate endogenous gene expression, as
is evidenced by the induction of Bcl-xS mRNA
we observed. In addition, our ﬁndings are consistent
with Bcl-x pre-mRNA splice switching as a possible
anti-tumor strategy in melanoma as well as other
malignancies expressing Bcl-xL.
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